ARWR Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Benzinga - Mentions: REGN CRSP

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

7 days ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

9 days ago - By: The Motley Fool

Privium Fund Management Sells Into Strength in Pharma Stock

10 days ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

16 days ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

2 months ago - By: Stocktwits - Mentions: NVS

Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’

3 months ago - By: The Motley Fool

Arrowhead (ARWR) Q3 Revenue Drops 41%

24 days ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

a month ago - By: Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

2 months ago - By: Benzinga - Mentions: SPY CORT QQQ ATRA ...

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

2 months ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

4 months ago - By: Stocktwits - Mentions: SRPT

Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement

2 months ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

2 months ago - By: Investor's Business Daily - Mentions: NVS

Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion

2 months ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

3 months ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

3 months ago - By: Yahoo Finance - Mentions: HI

Goodbye, Mag 7! These 3 Buy-Rated Small-Cap Stocks Are Starting to Outperform.

3 months ago - By: Yahoo Finance - Mentions: SRPT

Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue

3 months ago - By: Stocktwits - Mentions: SRPT

This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week

3 months ago - By: Investor's Business Daily - Mentions: SRPT

Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives

3 months ago - By: Stocktwits - Mentions: SRPT

Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial

3 months ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

3 months ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

3 months ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

4 months ago - By: Yahoo Finance - Mentions: SRPT

Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal

4 months ago - By: Bloomberg - Mentions: SRPT

Sarepta Owes $100 Million to Partner as Financial Pressure Grows

4 months ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

4 months ago - By: Investor's Business Daily - Mentions: RY RY.CA SRPT

Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe

4 months ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

4 months ago - By: Arrowhead Pharmaceuticals, Inc.

ARROWHEAD PHARMACEUTICALS IN (ARWR) Stock News

ARWR Latest News, Press Relases and Analysis

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Privium Fund Management Sells Into Strength in Pharma Stock

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’

Arrowhead (ARWR) Q3 Revenue Drops 41%

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Goodbye, Mag 7! These 3 Buy-Rated Small-Cap Stocks Are Starting to Outperform.

Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue

This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week

Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives

Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal

Sarepta Owes $100 Million to Partner as Financial Pressure Grows

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics